FINWIRES · TerminalLIVE
FINWIRES

欧洲、中东和非洲地区石油市场最新动态:原油价格反弹逾3%,市场担忧停火协议可能破裂。

-- 周四,原油期货价格上涨超过3%,原因是市场正在评估德黑兰方面指责美国已违反为期两周的停火协议。 近月穆尔班原油期货合约上涨3.7%,至每桶101.22美元。布伦特原油期货合约上涨3.8%,至每桶98.33美元。 荷兰国际集团(ING)分析师指出:“由于中东战事持续,停火前景恶化,霍尔木兹海峡局势的不确定性持续存在,油价因此反弹。” 在上个交易日跌破100美元后,由于脆弱的停火协议立即面临违反协议的指控,油价今日反弹。 荷兰国际集团(ING)分析师表示:“在德黑兰方面表示协议的几项条款已被违反后,人们对停火的乐观情绪消退。” 伊朗议会议长穆罕默德·巴格尔·加利巴夫在社交媒体上表示,美国已经违反了德黑兰提出的十点框架。 加利巴夫周三在X网站上发帖称,华盛顿违反了伊朗提出的十点方案中的三项条款。 他列举了美国违反黎巴嫩停火协议、美国无人机入侵伊朗领空以及否认伊朗铀浓缩权利等行为。 尽管达成了停火协议,伍德麦肯兹的分析师表示,中东地区的油气运输仍需时日,许多步骤和流程可能需要数月时间才能完成。 荷兰国际集团的分析师补充道:“由于短期内不太可能全面重新开放海峡,预计油价将继续得到支撑,因为与减产和炼油厂停工相关的干扰需要时间才能消除。”

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA